Navigation Links
China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
Date:3/3/2010

TAI'AN, China, March 3 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Company's management team will present at the Rodman & Renshaw Annual China Investment Conference March 7 to 9, 2010 in Beijing, China.

The date, time and location of China Biologic's presentation at the Rodman & Renshaw Annual China Investment Conference are as follows:

    Date:      Monday, March 8, 2010
    Time:      10:15 a.m. to 10:40 a.m.
    Presenter: Mr. Chaoming Zhao, Chief Executive Officer
               Mr. Ming Yin, VP of Finance and Investor Relations
    Venue:     The Regent Hotel - Ball Room III
               No. 99 Jinbao Street, Dongcheng District
               Beijing 100005, China

During the conference, management will be available for one-on-one meetings with institutional investors. Interested parties please contact Lily Khaykina at LK@rodm.com or (212) 430-1714. Participation in the R&R Conference is by invitation only.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:   http://www.chinabiologic.com

     Investor Relations Contact:
     Ms. Lei Huang, Account Manager
     CCG Investor Relations
     Tel:   +1-646-833-3417
     Email: lei.huang@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com

SOURCE China Biologic Products, Inc.

Back to top

RELATED LINKS
http://www.chinabiologic.com
http://www.ccgirasia.com

'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results
2. China Nepstar Chain Drugstore Announces Annual Dividend
3. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
4. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
5. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Candela Receives Registration Approval to Market Its Best-in-Class GentleMax and Alex TriVantage Lasers in China
8. Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China
9. Chinas Basic Medical Insurance to Cover Sinobiopharmas Flagship Product
10. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
11. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... planning services and products in the developing world, is pleased to release their ... prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Clearinghouse supporting the real time adjudication of medical service claims by Pharmacy Benefit ... their current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard ...
(Date:5/25/2016)... ... , ... The University of San Francisco (USF) has named Margaret Wooding Baker ... of more than 100 full-time faculty and staff, and serve as a member of ... , Baker comes to USF from the University of Washington in Seattle, where she ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
Breaking Medicine News(10 mins):